Cargando…

Reverse Transcription Can Critically Impact the Diagnostic Outcome of BCR::ABL1 Quantitative Real-Time RT-PCR

SIMPLE SUMMARY: Reverse transcriptases (RT) play a crucial role in BCR::ABL1 fusion transcript monitoring of chronic myeloid leukemia (CML). RT enzyme and reaction conditions may contribute to impairment of stoichiometry in cDNA synthesis potentially biasing in qRT-PCR data. We have comparatively in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Spiess, Birgit, Kleiner, Helga, Tarnopolscaia, Irina, Naumann, Nicole, Fabarius, Alice, Hofmann, Wolf-Karsten, Saussele, Susanne, Seifarth, Wolfgang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417499/ https://www.ncbi.nlm.nih.gov/pubmed/37568730 http://dx.doi.org/10.3390/cancers15153914

Ejemplares similares

The benefit of quality control charts (QCC) for routine quantitative BCR-ABL1 monitoring in chronic myeloid leukemia
por: Spiess, Birgit, et al.
Publicado: (2018)

Diagnostic performance of the molecular BCR-ABL1 monitoring system may impact on inclusion of CML patients in stopping trials
por: Spiess, Birgit, et al.
Publicado: (2019)

A new aberrantly spliced BCR‐ABL1 transcript variant (e13a1) identified in routine monitoring using different quantitative reverse transcription polymerase chain reaction techniques in a patient with chronic myeloid leukemia
por: Naumann, Nicole, et al.
Publicado: (2022)

Separase activity distribution can be a marker of major molecular response and proliferation of CD34(+) cells in TKI-treated chronic myeloid leukemia patients
por: Spiess, Birgit, et al.
Publicado: (2020)

Gene Expression Pattern of ESPL1, PTTG1 and PTTG1IP Can Potentially Predict Response to TKI First-Line Treatment of Patients with Newly Diagnosed CML
por: Christiani, Eva, et al.
Publicado: (2023)

c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia
por: Prinzhorn, Wiltrud, et al.
Publicado: (2016)

The Proteolytic Activity of Separase in BCR-ABL-Positive Cells Is Increased by Imatinib
por: Haaß, Wiltrud, et al.
Publicado: (2012)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy
por: Haaß, Wiltrud, et al.
Publicado: (2015)

DNA Damage and DNA Damage Response in Chronic Myeloid Leukemia
por: Popp, Henning D., et al.
Publicado: (2020)

Measurement of Separase Proteolytic Activity in Single Living Cells by a Fluorogenic Flow Cytometry Assay
por: Haaß, Wiltrud, et al.
Publicado: (2015)

Increased separase activity and occurrence of centrosome aberrations concur with transformation of MDS
por: Ruppenthal, Sabrina, et al.
Publicado: (2018)

Antileukemic Efficacy in Vitro of Talazoparib and APE1 Inhibitor III Combined with Decitabine in Myeloid Malignancies
por: Kohl, Vanessa, et al.
Publicado: (2019)

Proteins Marking the Sequence of Genotoxic Signaling from Irradiated Mesenchymal Stromal Cells to CD34+ Cells
por: Kohl, Vanessa, et al.
Publicado: (2021)

Impact of BCR::ABL1 transcript type on RT-qPCR amplification performance and molecular response to therapy
por: Salmon, Matthew, et al.
Publicado: (2022)

Chronic Myeloid Leukaemia with isolated massive thrombocytosis and BCR‐ABL1 detection failure using RT‐MLPA (positive RT‐qPCR)
por: Coster, Lucie, et al.
Publicado: (2021)

Genotoxic Bystander Signals from Irradiated Human Mesenchymal Stromal Cells Mainly Localize in the 10–100 kDa Fraction of Conditioned Medium
por: Kohl, Vanessa, et al.
Publicado: (2021)

Allosteric inhibition enhances the efficacy of ABL kinase inhibitors to target unmutated BCR-ABL and BCR-ABL-T315I
por: Mian, Afsar Ali, et al.
Publicado: (2012)

Evidence for Recombinant GRP78, CALR, PDIA3 and GPI as Mediators of Genetic Instability in Human CD34+ Cells
por: Fabarius, Alice, et al.
Publicado: (2022)

Performance Evaluation of the QXDx BCR-ABL %IS Droplet Digital PCR Assay
por: Chung, Hee-Jung, et al.
Publicado: (2020)

Targeting BCR-ABL(+) stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex
por: Chen, Min, et al.
Publicado: (2017)

Standardization of BCR-ABL1 p210 Monitoring: From Nested to Digital PCR
por: Jovanovski, Aleksandar, et al.
Publicado: (2020)

Digital PCR for BCR-ABL1 Quantification in CML: Current Applications in Clinical Practice
por: Kockerols, Camille C.B., et al.
Publicado: (2020)

Droplet Digital PCR for BCR–ABL1 Monitoring in Diagnostic Routine: Ready to Start?
por: Bochicchio, Maria Teresa, et al.
Publicado: (2021)

BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene
por: Sharma, Nitesh, et al.
Publicado: (2015)

Pterostilbene downregulates BCR/ABL and induces apoptosis of T315I-mutated BCR/ABL-positive leukemic cells
por: Kawakami, Shohei, et al.
Publicado: (2022)

A long distance RT-PCR able to amplify the Pestivirus genome
por: Jones, Leandro R., et al.
Publicado: (2006)

BCR: a new target in resistance mediated by BCR/ABL-315I?
por: Haberbosch, Isabella, et al.
Publicado: (2016)

The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins
por: You, Liangshun, et al.
Publicado: (2016)

Expanding the Diversity of Allosteric Bcr-Abl Inhibitors
por: Deng, Xianming, et al.
Publicado: (2010)

An In-House Method for Molecular Monitoring of BCR-ABL
por: Sercan, Hakkı Ogün, et al.
Publicado: (2012)

Depression of oncogenecity by dephosphorylating and degrading BCR-ABL
por: Gao, Miao, et al.
Publicado: (2016)

Activation-induced cytidine deaminase acts as a mutator in BCR-ABL1–transformed acute lymphoblastic leukemia cells
por: Feldhahn, Niklas, et al.
Publicado: (2007)

Leukocyte DNA damage after reduced and conventional absorbed radiation doses using 3rd generation dual-source CT technology
por: Popp, Henning D., et al.
Publicado: (2016)

AHI-1 interacts with BCR-ABL and modulates BCR-ABL transforming activity and imatinib response of CML stem/progenitor cells
por: Zhou, Liang L., et al.
Publicado: (2008)

The HSP90 inhibitor KW-2478 depletes the malignancy of BCR/ABL and overcomes the imatinib-resistance caused by BCR/ABL amplification
por: Zeng, Dachuan, et al.
Publicado: (2022)

The BCR-ABL1 Kinase Bypasses Selection for the Expression of a Pre–B Cell Receptor in Pre–B Acute Lymphoblastic Leukemia Cells
por: Klein, Florian, et al.
Publicado: (2004)

Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network
por: Schäfer, Vivien, et al.
Publicado: (2021)

Combined inhibition of BCR-ABL1 and the proteasome as a potential novel therapeutic approach in BCR-ABL positive acute lymphoblastic leukemia
por: Maletzke, Saskia, et al.
Publicado: (2022)

Crizotinib acts as ABL1 inhibitor combining ATP-binding with allosteric inhibition and is active against native BCR-ABL1 and its resistance and compound mutants BCR-ABL1(T315I) and BCR-ABL1(T315I-E255K)
por: Mian, Afsar Ali, et al.
Publicado: (2021)

Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis
por: Baum, Karina J, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_20iobdegeqtncoadvcm22c7vln